Hinge Health, Inc.

Judi Health™, the enterprise health technology company and benefits administrator, announced three new partners to its clinical ecosystem: Color Health, operator of the nation's first ASCO-Certified Virtual Cancer Clinic; WellTheory, a solution for autoimmune and inflammatory conditions; and Cylinder, a gastrointestinal care program recently acquired by Hinge Health. These additions join existing partners such as Sword Health and Progyny, expanding the range of specialized care programs available through Judi's unified benefits platform. The announcement comes as employer plan sponsors face projected healthcare cost increases of over 7% next year and new requirements under the Consolidated Appropriations Act of 2026. Judi Health's platform aims to reduce administrative complexity and improve care coordination, with partners demonstrating significant outcomes: Color Health reports up to 77% higher cancer screening rates and average savings of $62,000 per patient; Cylinder shows over 85% of members report symptom improvement within 90 days and a 25% reduction in GI pharmacy spend; and WellTheory has led to 64% fewer emergency room visits among members. All three solutions are immediately available to Judi Health plan sponsors.

Hinge Health raised its full-year 2026 revenue guidance to $856 million to $860 million and announced a definitive agreement to acquire Cylinder Health for $105 million in cash. The company reported second-quarter revenue of $213 million, beating expectations, with operating income of $62 million and an operating margin that expanded to 29 percent from 19 percent. The raised outlook includes an expected $7 million to $8 million contribution from Cylinder, which is set to close around the end of August or early September and will support a broader gastrointestinal health rollout targeted for 2027. CEO Daniel Perez said the acquisition gives Hinge Health an 18- to 24-month head start in GI, with Cylinder bringing nearly 100 clients covering 2 million lives and established partnerships with two of the three largest pharmacy benefit managers and three of the top five national health plans. The company also highlighted momentum in its Migraine Care Program, now with over 450 clients and more than 5 million covered lives, and said its active pipeline remains ahead of last year, including a Fortune 15 win displacing a competitor for nearly 300,000 lives.

Hinge Health shares rose sharply in the second quarter after the company reported a substantial earnings beat and raised its full-year guidance, driven by accelerating bookings as clients added more eligible lives and yields improved. The Meridian Small Cap Growth Fund highlighted the healthcare technology company in its Q2 2026 investor letter, citing its dominant position in a large, underpenetrated musculoskeletal care market, improving per-member economics, and a widening product suite. Management reinforced the momentum at its inaugural investor day with new long-term growth and margin targets and strong early reception for its new migraine product. The fund noted the stock advanced despite broader market wariness toward digital health. Hinge Health closed at $74.06 per share on July 29, 2026, with a market capitalization of $5.73 billion.

Hinge Health raised its full-year revenue guidance to $798–804 million, implying 37% annual growth, after first-quarter revenue of $182 million beat expectations. The company also increased its expected net income to $215 million from $156 million. Trailing twelve-month billings surged to $769.9 million, driven by a record quarterly increase of $98.5 million. Projected 2026 operating margins improved to 26% from 21%, supported by an 85% gross margin and a debt-free balance sheet with $316 million in cash.